Who are PIASKY's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Piasky, Eculizumab (Soliris®), BOL-303259-X, Spacing of Eculizumab infusions, Eculizumab Injection, C5 Inhibitor.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/crovalimab-akkz.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-06-10 · How we verify

PIASKY — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

PIASKY (CROVALIMAB-AKKZ) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Complement C5 Inhibitor [EPC]. Area: Other.

marketed Complement C5 Inhibitor [EPC] Other Live · refreshed every 30 min

Target snapshot

PIASKY (CROVALIMAB-AKKZ) — GENENTECH INC.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
PIASKY TARGET	CROVALIMAB-AKKZ	GENENTECH INC	marketed	Complement C5 Inhibitor [EPC]
Piasky	CROVALIMAB	Genentech Inc	marketed	Complement C5 Inhibitor [EPC]		2025-01-01
Eculizumab (Soliris®)	Eculizumab (Soliris®)	Massachusetts General Hospital	marketed	Complement C5 inhibitor	Complement protein C5
BOL-303259-X	BOL-303259-X	Bausch & Lomb Incorporated	phase 3	Complement C5 inhibitor	Complement C5
Spacing of Eculizumab infusions	Spacing of Eculizumab infusions	University Hospital, Tours	phase 3	Complement C5 inhibitor	Complement protein C5
Eculizumab Injection	Eculizumab Injection	Wuhan Createrna Science and Technology Co., Ltd	phase 3	Complement C5 inhibitor	C5 (Complement protein 5)
C5 Inhibitor	C5 Inhibitor	Alexion Pharmaceuticals, Inc.	phase 3	Complement C5 inhibitor	C5

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Complement C5 Inhibitor [EPC] class)

GENENTECH INC · 1 drug in this class
Genentech Inc · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). PIASKY — Competitive Intelligence Brief. https://druglandscape.com/ci/crovalimab-akkz. Accessed 2026-06-10.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing